Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Cassinat

Showing results (1-10 of 134) with videos related to

Pageof 14
Sort By:
American Journal of Hematology|March 4, 2023
Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategiesJean-Jacques Kiladjian, Bruno Cassinat
Blood|October 16, 2012
Live and let (MPN cells) die!Bruno Cassinat, Jean-Jacques Kiladjian
The New England Journal of Medicine|July 10, 2014
Interferon alfa therapy in CALR-mutated essential thrombocythemiaBruno Cassinat, Emmanuelle Verger, Jean-Jacques Kiladjian
The New England Journal of Medicine|October 6, 2017
Clonal Hematopoiesis and AtherosclerosisBruno Cassinat, Claire Harrison, Jean-Jacques Kiladjian
Expert Review of Hematology|June 5, 2019
How much does 2016 WHO classification of myeloproliferative neoplasms affect the clinic?Bruno Cassinat, Stephane Giraudier, Jean-Jacques Kiladjian
Thrombosis Research|August 19, 2015
Low incidence of CALR gene mutations in patients with cerebral venous thrombosis without overt chronic myeloproliferative neoplasmEmmanuelle Verger, Isabelle Crassard, Bruno Cassinat, et al.
Cellular Signalling|August 22, 2012
Regulation of the transcriptional activity of nuclear receptors by the MEK/ERK1/2 pathwayFabien Zassadowski, Cecile Rochette-Egly, Christine Chomienne, et al.
Thrombosis and Haemostasis|June 4, 2008
The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorderSylvia Bellucci, Bruno Cassinat, Nadine Bonnin, et al.
Leukemia|March 31, 2023
Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscapeNabih Maslah, Lina Benajiba, Stephane Giraudier, et al.
British Journal of Haematology|January 18, 2014
TET2 gene sequencing may be helpful for myeloproliferative neoplasm diagnosisEmmanuelle Verger, Annalisa Andreoli, Christine Chomienne, et al.
Pageof 14

Showing results (1-10 of 134) with videos related to

Sort By:
Pageof 14
American Journal of Hematology|March 4, 2023
Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategiesJean-Jacques Kiladjian, Bruno Cassinat
Blood|October 16, 2012
Live and let (MPN cells) die!Bruno Cassinat, Jean-Jacques Kiladjian
The New England Journal of Medicine|July 10, 2014
Interferon alfa therapy in CALR-mutated essential thrombocythemiaBruno Cassinat, Emmanuelle Verger, Jean-Jacques Kiladjian
The New England Journal of Medicine|October 6, 2017
Clonal Hematopoiesis and AtherosclerosisBruno Cassinat, Claire Harrison, Jean-Jacques Kiladjian
Expert Review of Hematology|June 5, 2019
How much does 2016 WHO classification of myeloproliferative neoplasms affect the clinic?Bruno Cassinat, Stephane Giraudier, Jean-Jacques Kiladjian
Thrombosis Research|August 19, 2015
Low incidence of CALR gene mutations in patients with cerebral venous thrombosis without overt chronic myeloproliferative neoplasmEmmanuelle Verger, Isabelle Crassard, Bruno Cassinat, et al.
Cellular Signalling|August 22, 2012
Regulation of the transcriptional activity of nuclear receptors by the MEK/ERK1/2 pathwayFabien Zassadowski, Cecile Rochette-Egly, Christine Chomienne, et al.
Thrombosis and Haemostasis|June 4, 2008
The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorderSylvia Bellucci, Bruno Cassinat, Nadine Bonnin, et al.
Leukemia|March 31, 2023
Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscapeNabih Maslah, Lina Benajiba, Stephane Giraudier, et al.
British Journal of Haematology|January 18, 2014
TET2 gene sequencing may be helpful for myeloproliferative neoplasm diagnosisEmmanuelle Verger, Annalisa Andreoli, Christine Chomienne, et al.
Pageof 14